|
News For BMY;PFE;DUF;CG;HLF;CALM From The Last 14 Days Check below for free stories on BMY;PFE;DUF;CG;HLF;CALM the last two weeks. |
|
|
| June 12, 2013 |
| 13:15 EDT |  | BMY | Bristol-Myers, AstraZeneca issue statement on review of some therapies
 Subscribe for More Information |
|
| 08:28 EDT | | PFE | Teva to pay $1.6B to settle with Pfizer, Nycomed over generic Protonix
Subscribe for More Information |
|
| 08:02 EDT | | PFE | Pfizer wins $2.15B settlement from Teva and Sun for patent infringement
Subscribe for More Information |
|
| 06:34 EDT | | HLF | Herbalife says survey indicates 7.9M customers in U.S.
Herbalife last night released the results of a study conducted to determine the penetration of Herbalife distributors and end users in the U.S. Herbalife engaged Nielsen, to conduct the research. Conducted online during April and May, the survey was completed without intervention from Herbalife and the company’s sponsorship was not disclosed, it added. With a sample size of 10,525 consumers, the survey had a margin of error of +/- 0.96%. According to the research, 3.3% of the general population reported that they had purchased Herbalife products within the past three months, indicating that Herbalife currently has approximately 7.9M customers when projected to the total U.S. adult population. Herbalife customers would include their distributor network, which totaled approximately 550,000 in the U.S. as of the end of Q1. "“This survey, conducted by one of the world’s most respected research organizations, confirms what we at Herbalife already know to be true: that Herbalife’s products have a broad consumer base here in the U.S. – nearly 8 million in the last three months – and that the majority of individuals that purchase Herbalife products do so for personal consumption," the company said. |
|
| 06:33 EDT |  | HLF | Herbalife volatility at low end of nine-month range
Subscribe for More Information |
|
| June 11, 2013 |
| 18:09 EDT | | BMY | Orencia trial data shows efficacy rate comparable to Humira
Bristol-Myers announced the results of year two data from AMPLE, a trial of 646 patients comparing the subcutaneous formulation of Orencia, or abatacept, vs. Humira, or adalimumab, each on a background of MTX, in biologic naïve patients with moderate to severe RA. The AMPLE year two data are being presented this week at the European League Against Rheumatism annual congress and highlighted during a congress press conference. AMPLE met its primary endpoint as measured by non-inferiority of ACR20 at year one. The Orenica regimen achieved comparable rates of efficacy vs. the Humira regimen, or 64.8% vs. 63.4%, respectively. Onset of response was also generally similar for the two groups. Year two of the study remained investigator-blinded. At year two, the Orencia regimen achieved the same rate of efficacy as the Humira regimen based on ACR20. |
|
| 16:00 EDT | | PFE | Options Update; June 11, 2013
Subscribe for More Information |
|
| 15:15 EDT | | PFE | Pfizer June volatility at one-year high
Subscribe for More Information |
|
| 08:01 EDT |  | BMY | Leerink's major pharma and biotech analysts hold a conference call
Subscribe for More Information |
|
| 07:42 EDT | | PFE | Boston Biotech Conferences to host a conference
Subscribe for More Information |
| |
| 05:46 EDT |  | CG | Market for high-priced skyscrapers grows, WSJ reports
Subscribe for More Information |
|
| June 10, 2013 |
| 07:40 EDT | | PFE | Leerink's biotech analyst holds analyst/industry conference call on ASCO
Subscribe for More Information |
|
| 07:20 EDT | | PFE | Biomed to host a conference
Subscribe for More Information |
|
| June 7, 2013 |
| 13:49 EDT | | BMY | Bristol-Myers volatility elevated as shares pullback from 11-year high
Subscribe for More Information |
|
| June 6, 2013 |
| 11:04 EDT | | BMY | Bristol-Myers says Health Canada expands Abilify indications
Abilify has received an additional approval from Health Canada as an adjunct, or add-on, treatment to antidepressants for the treatment of major depressive disorder in adults who had an inadequate response to prior antidepressant treatments during the current episode. |
|
| 08:43 EDT | | CG | Carlyle Group volatility increases as shares trade at 18-week lows
Carlyle Group overall option implied volatility of 34 is above its 26-week average of 31 according to Track Data, suggesting larger price movement. |
|
| 06:04 EDT |  | CG | Carlyle Group 11.1M share Secondary priced at $27.00
Citigroup, Credit Suisse and JPMorgan acted as joint book running managers for the offering. |
|
| June 5, 2013 |
| 10:07 EDT |  | CG | On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Audience (ADNC) initiated with a Hold at Benchmark Co.... Bank of Ireland (IRE) initiated with an Underweight at HSBC... Ellie Mae (ELLI) initiated with an Outperform at FBR Capital... Haemonetics (HAE) initiated with an Outperform at William Blair... Jive Software (JIVE) initiated with a Buy at Janney Capital... Northern Tier (NTI) initiated with a Buy at Citigroup... Workday (WDAY) initiated with a Market Perform at FBR Capital... Carlyle Group (CG) initiated with a Buy at Sandler O'Neill... XL Group (XL) initiated with a Neutral at Nomura... Travelers (TRV) initiated with a Neutral at Nomura... Marsh & McLennan (MMC) initiated with a Neutral at Nomura... Aon plc (AON) initiated with a Neutral at Nomura... Allstate (ALL) initiated with a Neutral at Nomura... AIG (AIG) initiated with a Neutral at Nomura... ACE Ltd. (ACE) initiated with a Buy at Nomura... Progressive (PGR) initiated with a Reduce at Nomura... First Solar (FSLR) coverage assumed with a Sell at Maxim... Jive Software (JIVE) reinstated with a Neutral at Credit Suisse... Standard Pacific (SPF) initiated with a Buy at BofA/Merrill... Axiall (AXLL) initiated with a Buy at BofA/Merrill. |
|
| 09:03 EDT | | CG | Carlyle Group initiated with a Buy at Sandler O'Neill
Target $36. |
|
| 05:55 EDT | | HLF | Stocks with implied volatility movement; CRM HLF
Stocks with implied volatility movement; Salesforce.com (CRM), Herbalife (HLF) according to IVolatility. |
| |
|
|
|
|
